1. Schedule dependency of the anti-leukaemic activity of the podophyllotoxin-derivative VP16–213 in L1210 leukaemia;Dombernofsky;Acta Pathol Microbiol Scand [A],1973
2. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung;Roed;Cancer Chemother Pharmacol,1987
3. Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents;Sullivan;Nci Monogr,1987
4. Survival and cell-cycle progression delay of human lymphoma cells in vitro exposed to VP16–213;Drewinko;Cancer Treat Rep,1976
5. VP16–213 monotherapy for remission induction of small cell lung cancer. A randomised trial using three dosage schedules;Cavalli;Cancer Treat Rep,1978